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CASE REPORT 
Clinical Utility of Molecular Profiling in Recurrent 
Glioblastoma Multiforme
Rebecca P Bystrom MD,1 Pavalan Selvam MBBS,2 Jens Rueter MD,3 Honey V Reddi PhD,4  Christine Lu-
Emerson MD1
1Department of Neurology, Maine Medical Center, Portland ME, 2The Jackson Laboratory for Genomic Medicine, Farmington, 
CT, 3The Maine Cancer Genomics Initiative, The Jackson Laboratory, Augusta, ME, 4Medical College of Wisconsin, 
Milwaukee, WI
Introduction:  Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor found 
in adults. GBM has limited therapeutic options. Initial tumor sampling establishes the histopathologic 
diagnosis, identifies prognostic and therapeutic biomarkers, and provides an opportunity for molecular 
profiling. By contrast, the utility of repeat tumor sampling and molecular profiling in recurrent GBM is not 
well established.
Clinical Findings: We present a 69-year-old woman with GBM whose tumor recurred after standard treatment with 
temozolomide (TMZ) and concurrent radiation, followed by adjuvant TMZ. This patient had a methylated 
O6-methylguanine-DNA methyltransferase (MGMT) promoter, which ordinarily predicts a favorable 
response to TMZ.
 Our patient’s recurrent tumor was rechallenged with TMZ based on persistent methylation of the MGMT 
promoter. However, her tumor was refractory to TMZ, and she floridly progressed through multiple 
treatments. We performed retrospective molecular profiling using next-generation sequencing (NGS) 
on her recurrent tumor. The NGS results showed a TMZ hypermutation signature that confers resistance 
to TMZ. This signature impacted our patient’s treatment plan in real time and prompted an immediate 
discontinuation of TMZ.
Conclusions:  Advances in NGS provide further insight into the molecular landscape of GBM. As NGS becomes 
more timely and cost-effective, molecular profiling of recurrent tumors could impact treatment decisions 
through either avoiding a particular treatment paradigm or identifying a potential targetable mutation. For 
this reason, we suggest that clinical practice routinely consider repeat biopsy and molecular profiling for 
recurrent GBM.
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A 69-year-old woman presented with weakness and paresthesia in her right lower extremity. Magnetic resonance imaging (MRI) of the 
brain showed enhancing lesions at the left fronto-
parietal junction and in the left occipito-parietal lobe 
(Figure 1A and 1B). Complete resection of the left 
occipital lesion revealed a isocitrate dehydrogenase 
1 (IDH1) wildtype glioblastoma multiforme 
(GBM) with a methylated O6-methylguanine-DNA 
methyltransferase (MGMT) promoter. Sequencing 
was not performed as it was not routinely available 
at that time. The patient proceeded with 6 weeks of 
chemoradiation with TMZ and 12 cycles of adjuvant 
TMZ. Bevacizumab, a recombinant humanized 
monoclonal antibody against vascular endothelial 
growth factor, was added for pseudo-progression.
Four months after treatment cessation, a 
surveillance MRI showed a new enhancing lesion 
in the contralateral frontal lobe (Figure 1C). 
Repeat biopsy showed an MGMT methylated IDH1 
wildtype recurrent GBM. Due to MGMT methylation 
status, the patient was rechallenged with a hypo-
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fractionated course of chemoradiation with TMZ. 
Yet the next MRI showed frank progression. 
Bevacizumab was initiated as monotherapy before 
reintroducing adjuvant TMZ. The patient progressed 
with new enhancement in the left temporal lobe 
(Figure 1D).
Molecular profiling (ActionSeq Plus/ActionSeq 
Plus 2.0 by the Jackson Laboratory for Genomic 
Medicine, Farmington, CT) of the patient’s recurrent 
tumor revealed a ‘TMZ hypermutation signature.’1 
This signature had an MSH6 mutation and 153 
variants of unknown clinical significance and 261 
genomic events with C>T transitions compared to 
175 genomic events with C>T transitions in the 
original tumor. Based on this hypermutation profile, 
we discontinued TMZ and started pembrolizumab 
(an antibody against programmed cell death 
protein-1 and approved for MSH6 mutations) and 
bevacizumab. Unfortunately, the tumor became too 
invasive, with diffuse involvement of the brain. After 
6 weeks of treatment, the patient was transitioned 
to hospice.
DISCUSSION
Initial tumor sampling after surgical resection 
of GBM enables histopathologic diagnosis and 
molecular testing that assesses prognostic and 
therapeutic biomarkers. The methylation status 
of the MGMT promoter is one of the strongest 
prognostic and predictive biomarkers in GBM.2 This 
MGMT promoter methylation is associated with a 
more favorable response to TMZ and improved 
overall survival.2,3 When methylated, the MGMT 
promoter silences the MGMT gene, which leads to 
fewer successful repairs of O6-meG, the byproduct 
of TMZ treatment.1
In recurrent GBM, there are limited treatment 
options and no prognostic or therapeutic 
biomarkers. Treatment often consists of adjusting 
chemotherapeutic or biologic agents, and it may 
involve reintroducing alkylating agents, such as 
TMZ or lomustine. Bevacizumab, an antiangiogenic 
agent, has also been approved for use in recurrent 
GBM.4
Repeating a brain biopsy solely for the purpose of 
molecular analysis of recurrent GBM is not routine 
clinical practice. Surgery is reserved for significant 
debulking as it confers a survival advantage.5,6 In 
clinical practice, it is often assumed recurrent GBM 
tumors harbor the same molecular features as the 
initial tumor. For instance, if the newly diagnosed 
GBM has a methylated MGMT promoter, the 
assumption is that the MGMT promoter will remain 
methylated at recurrence and confer the same 
prognostic and predictive value. However, different 
molecular phenotypes can emerge at recurrence 
and only be revealed with repeat molecular profiling.
To illustrate, the TMZ hypermutation phenotype is 
associated with TMZ resistance. This phenotype 
can emerge in recurrent GBMs that are initially 
exposed to TMZ. When tumors with a methylated 
MGMT promoter are treated with TMZ, the 
increased O6-meG adducts are funneled toward 
the mismatch repair pathway1. If tumor cells acquire 
mutations in any component of this pathway, such 
as the MSH6 gene, then G:C>A:T transitions 
can accumulate, preventing tumor cell death. 
This ‘TMZ hypermutation signature’1 creates a 
survival advantage for the recurrent tumor. This 
hypermutation signature can only be identified 
by repeat biopsy and molecular profiling in the 
recurrent tumor. Uncovering the hypermutation 
signature can prevent further exposure to TMZ and 
may dictate new treatment paradigms, including 
those that incorporate immunotherapy.7
The TMZ hypermutation signature cannot be 
detected using conventional laboratory testing. Its 
detection requires molecular profiling using high-
throughput technologies such as next-generation 
sequencing (NGS), which is now readily available 
through academic and commercial laboratories. 
NGS typically analyses 50 to 500 cancer-related 
genes in parallel. It enables the identification of 
new comprehensive biomarkers and also assesses 
a tumor’s mutational burden. Various applications 
of NGS can be developed to bypass concerns 
regarding the timely application of this technology 
in the clinical setting.  For instance, to identify the 
TMZ hypermutation phenotype, a rapid assessment 
of the number of G:C>A:T transitions and tumor 
mutational burden may suffice.  Our local laboratory 
estimates that the presence or absence of the 
hypermutation phenotype could be communicated 
to clinicians as quickly as 7 to 10 days.  
There are technical limitations to using NGS 
sequencing in GBM, including the amount of 
tissue needed for testing and the degree of 
neoplastic content in tumor samples. Cost is also a 
consideration if incorporating additional molecular 
testing into the management algorithm. While NGS 
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can be cost-effective, the reimbursement model in 
clinical practice has not been fully established.8
The utility of repeat biopsy for molecular profiling 
in recurrent GBM has not been previously 
established. We present a case in which repeat 
molecular profiling could have provided guidance 
for treatment. Despite the change in treatment, 
the patient rapidly progressed, underscoring the 
challenges in treating recurrent GBM. Earlier 
application of pembrolizumab may have been 
more beneficial. Timely incorporation of molecular 
profiling for recurrent GBM may guide appropriate 
targeting of mutations or avoidance of specific 
chemotherapeutic agents.
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Figure 1. Axial post-contrast T1 MRI brain. (A) Original MRI showed enhancing lesion in left occipital 
lobe. This was treated with gross total resection. (B) Original MRI showed separate enhancing lesion in 
the left frontal lobe in the original MRI brain. (C) Surveillance MRI showed first recurrence in the right 
frontal lobe. Review of prior radiation map showed that this area was outside of the radiation field. This 
lesion was treated with gross total resection. (D) Surveillance MRI showed second recurrence in the left 
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